Loading...
XTAI
1795
Market cap1.49bUSD
Oct 08, Last price  
180.50TWD
1D
-1.10%
1Q
-11.52%
Jan 2017
201.34%
IPO
906.13%
Name

Lotus Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XTAI:1795 chart
P/E
10.05
P/S
2.31
EPS
17.96
Div yield, %
3.20%
Shrs. gr., 5y
1.45%
Rev. gr., 5y
13.84%
Revenues
20.51b
+10.36%
606,822,000590,184,000532,209,000503,153,000658,481,0002,310,021,0005,521,937,0005,902,566,0006,423,760,0006,428,894,0009,174,740,00010,728,583,00012,649,189,00014,632,772,00016,957,971,00018,584,227,00020,509,474,000
Net income
4.72b
-6.82%
3,117,00015,051,000-38,403,000-193,234,00011,882,000-442,127,000103,949,000-134,041,0007,685,00099,476,000662,807,0001,026,796,0001,403,371,0003,020,757,0004,105,626,0005,065,510,0004,720,053,000
CFO
7.48b
+21.56%
89,499,00059,194,000-76,294,000-54,453,000-95,837,000-1,032,408,0001,077,573,0001,233,001,000592,293,000796,978,000302,809,0001,948,682,000119,662,0003,719,418,0001,614,207,0006,154,866,0007,481,979,000
Dividend
Aug 31, 20262.5987 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.

Key people

Chairman of the Board · since 2018
Eeling Chan
Chief Financial Officer, Deputy General Manager-Finance & Accounting · since 2016
Vamsi Kosaraju
Chief Operating Officer · since 2024
Gwen Hsieh
Chief Information Officer · since 2021
Venkata Yarasani
Chief Scientific Officer · since 2026
Edin Buljubasic
Deputy General Manager-Legal and Compliance · since 2022
Deputy General Manager-Research & Development · since 2019
Prashant Godse
Deputy General Manager-Business Development · since 2024
Mayank Mathuriya
Deputy General Manager-Global Business Development · since 2026
Bjartur Shen
Deputy General Manager - Strategy and Finance · since 2024
Valerie Lau
Chef Commercial Officer-APAC · since 2024
Susan Liao
Corporate Governance Officer · since 2024
Nat Ativitavas
Director · since 2023
Arni Hardarson
Director · since 2024
Yves Hermes
Director · since 2022
Orakul Suebsiri
Director · since 2025
Oranee Tangphao
Director · since 2022
Krisana Winitthumkul
Director · since 2022
Karl Karlsson
Independent Director · since 2023
Independent Director · since 2015
IPO date
Dec 13, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT